Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Net Equity Issued and Repurchased of $187000.0 for Q3 2025, up 44.96% quarter-over-quarter from $129000.0 in Q1 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $187000.0 for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $187000.0; the TTM figure through Sep 2025 stood at $39.5 million (changed N/A YoY), while the FY2024 annual figure was $39.2 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at $187000.0, up from $129000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $39.2 million in Q4 2024, with the low at $129000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 187,000.00 |
| Mar 31, 2025 | 129,000.00 |
| Dec 31, 2024 | 39.20 Mn |
| Jun 30, 2020 | 64.60 Mn |
| Sep 30, 2018 | 40.70 Mn |
| Sep 30, 2017 | 2.00 Mn |
| Jun 30, 2017 | 19.70 Mn |